Gallagher J Christopher, Rapuri Prema B, Smith Lynette M
Bone Metabolism Unit, Creighton University Medical Center, School of Medicine, 601 North 30th Street, Room 6718, Omaha, Nebraska 68131, USA.
J Clin Endocrinol Metab. 2007 Jan;92(1):51-8. doi: 10.1210/jc.2006-1153. Epub 2006 Oct 10.
Decreased calcitriol production due to impaired renal function may be a significant risk factor for falls in normal aging population.
The objective of the study was to examine the association between creatinine clearance (CrCl) and the incidence of falls and fallers in groups treated with placebo, calcitriol, estrogen therapy (ET)/estrogen + progestin therapy (HT), and calcitriol + ET/HT.
This was a 3-yr, double-blind, placebo-controlled study designed to test the efficacy of calcitriol and ET/HT on bone loss and falls with analysis by intention to treat and post hoc.
The study was conducted at an academic outpatient center.
Four hundred eighty-nine normal elderly women aged 65-77 yr; 415 women completed the study.
Subjects were randomized to placebo, calcitriol 0.25 mug twice a day, ET daily (conjugated equine estrogens 0.625 mg), HT (conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg) and calcitriol + ET/HT.
Cumulative number of falls and fallers were compared between groups with 24-h urine CrCl less than 60 and 60 ml/min or greater.
Calcitriol treatment decreased the number of fallers and falls. Low CrCl less than 60 ml/min was a predictor of the number of falls per person but not fallers in the placebo group (P = 0.007). In the low CrCl group (<60 ml/min), the rate of falls decreased on calcitriol by 53% [95% confidence interval (CI) -71% to -22%; P = 0.003], calcitriol + ET/HT by 61% (95% CI -76% to -37%; P = 0.001), and ET/HT by 25% (95% CI: -55% to +24%; not significant). Calcitriol reduced the rate of falls by 30% (95% CI -49% to -4%; P = 0.027) in the CrCl 60 ml/min or greater group.
Calcitriol treatment decreases falls in all subjects but especially in elderly women with decreased renal function (<60 ml/min) and frequent fallers.
由于肾功能受损导致骨化三醇生成减少可能是正常老年人群跌倒的一个重要危险因素。
本研究的目的是探讨肌酐清除率(CrCl)与接受安慰剂、骨化三醇、雌激素治疗(ET)/雌激素+孕激素治疗(HT)以及骨化三醇+ET/HT治疗的人群中跌倒发生率和跌倒者之间的关联。
这是一项为期3年的双盲、安慰剂对照研究,旨在测试骨化三醇和ET/HT对骨质流失和跌倒的疗效,并采用意向性分析和事后分析。
该研究在一个学术门诊中心进行。
489名年龄在65 - 77岁的正常老年女性;415名女性完成了研究。
受试者被随机分为安慰剂组、每天两次服用0.25μg骨化三醇组、每日ET组(结合马雌激素0.625mg)、HT组(结合马雌激素0.625mg + 醋酸甲羟孕酮2.5mg)以及骨化三醇+ET/HT组。
比较24小时尿CrCl小于60和60ml/min及以上的组之间跌倒的累积次数和跌倒者数量。
骨化三醇治疗减少了跌倒者数量和跌倒次数。在安慰剂组中,CrCl低于60ml/min是每人跌倒次数的一个预测因素,但不是跌倒者的预测因素(P = 0.007)。在CrCl低的组(<60ml/min)中,骨化三醇使跌倒率降低了53% [95%置信区间(CI)-71%至-22%;P = 0.003],骨化三醇+ET/HT使跌倒率降低了61%(95% CI -76%至-37%;P = 0.001),ET/HT使跌倒率降低了25%(95% CI:-55%至+24%;无显著性差异)。在CrCl为60ml/min及以上的组中,骨化三醇使跌倒率降低了30%(95% CI -49%至-4%;P = 0.027)。
骨化三醇治疗可减少所有受试者的跌倒次数,尤其是肾功能下降(<60ml/min)的老年女性和经常跌倒者。